Date:11/14/2012

tion of To Go Brands^® Nutraceutical Brand PlatformOn September 28, 2012, Cardium acquired the business assets and product portfolio of To Go Brands^® to support the expansion of Cardium's health sciences nutraceutical platform and to provide a revenue platform for the potential growth of the business.  With a portfolio of over 25 products, To Go Brands' nutraceutical powder mixes, supplements and chews are being sold through mass, food and drug channel retailers and To Go Brands' web-based store.  To Go Brands' experienced management team has key contacts and a track record of developing and placing new and innovative health and nutraceutical products into retail channels.  To Go Brands has now assumed operational responsibility for Cardium's nutraceutical initiative, which includes the Company's strategic investment in SourceOne Global Partners, a leading supplier of science-based ingredients and proprietary formulas, and the MedPodium Nutra-Apps^® product line. 

The acquisition of To Go Brands is part of Cardium's long-term business strategy and opportunistic diversification strategy.  Large pharmaceutical companies have entered the nutraceutical market and are diversifying their product lines with dietary-supplement products with large market potential and without the extensive regulatory hurdles.  In February 2012, Pfizer acquired privately-held Alacer Corp., the maker and distributor of Emergen-C^®, a vitamin C product. Schiff Nutrition International recently purchased Airborne, Inc., a leading provider of immune support products, and on October 30, 2012, Bayer HealthCare announced its acquisition of Schiff Nutritional International.

About To Go Brands^® Since 2007, To Go Brands has been making healthy, great tasting and anti-oxidant-rich phytonutrients and nutraceutical supplements in an array of easy use formats, including drink mixes, chew
'/>"/>

SOURCE Cardium Therapeutics Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Related medicine technology :

1. Cardium Exhibiting Its New FDA-Cleared Excellagen® At The 2012 Spring Symposium Of Advanced Wound Care
2. Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion
3. Cardium to Present at Sachs Associates 2012 Science, Partner, and Investment Forum: Gateway for the Global Life Sciences
4. Cardium Announces Plans For Commercializaton Of Excellagen® In The Russian Federation
5. Cardium Presents Second Quarter 2012 Financial Results And Reports On Recent Developments
6. Cardium Announces Excellagen Poster Presentatons At Desert Foot 9th Annual High Risk Diabetic Foot Conference
7. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
8. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
9. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
10. Grant & Eisenhofer Represents Lead Whistleblower in Historic $1.6 Billion Settlement with Abbott Laboratories Over Off-Label Marketing of Antiepileptic Medication Depakote
11. Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ®